【价值发现】百奥赛图:生物技术平台将迎来高速增长

大众证券报
Jan 16

百奥赛图(688796)以基因编辑技术起家,是一家创新药临床前CRO及生物技术公司,专门为创新药企业提供抗体药物发现及临床前研发服务,目前产品和服务主要涉及基因编辑模式动物制备、创新模式动物繁殖与供应、临床前药理药效评价以及抗体药物发现等四大应用领域。过去5年,公司营业收入保持高速增长,2024年正式实现扭亏为盈;2025年前三季度实现收入9.41亿元,同比增长59.50%;归母净利润1.14亿元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10